Sanofi is a leading pharmaceutical company based in Paris, France, founded in 1973. The company operates in over 100 countries worldwide, specializing in immunology, oncology, neurology, and vaccines.
📊 Financial Performance (2024–2025)
2024:
-
Annual Revenue: €41.1 billion (11.3% growth from the previous year)
-
Earnings Per Share (EPS): €7.12 (4.1% growth)
-
Net Profit: €4.59
-
R&D Expenditures: €7.4 billion (14.6% increase)
-
Dividends: €3.92 (30 years of growth)
2025 Outlook:
-
Revenue Growth: Strong single-digit growth expected
-
EPS Growth: Double-digit increase anticipated
-
Share Buyback Program: €5 billion
💊 Key Products and Achievements
-
Dupixent: Used for treating atopic dermatitis and asthma. In 2024, it generated over €13 billion in revenue, with expectations to reach €22 billion by 2030.
-
Beyfortus: A new RSV (respiratory syncytial virus) vaccine, with first-year sales of €1.7 billion.
-
ALTUVIIIO, Nexviazyme, Rezurock: New drugs, showing a 67% increase in 2024.
-
Cerdelga, Kevzara, Efluelda: New drugs and vaccines approved in the EU and US.
🧬 Innovations and Strategy
-
AI Integration: Sanofi is utilizing AI in drug discovery and development to improve research efficiency.
-
R&D Investments: In 2024, R&D expenditures were €7.4 billion, underlining the company’s commitment to innovation.
-
Opella Divestment: In 2025, Sanofi plans to sell its consumer healthcare division, refocusing on scientific research and innovation.
-
UK Collaboration: Sanofi is working to increase demand for new drugs and reduce bureaucratic barriers in the UK.
📈 Stocks and Investments
-
Stock Ticker: SAN (Euronext Paris)
-
Stock Price (May 2025): Around €100
-
Dividend Yield: Stable, attractive for long-term investors
Conclusion: Sanofi is an innovative company with a strong focus on scientific research and development. It continues to lead the pharmaceutical industry with a robust product portfolio and ongoing investment in new therapies.